Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,101–11,200 of 15,747
The effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines
Sharma, R., & Anand, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266271 · Cited by 2
Sentiment Analysis Of Twitter Data Towards COVID-19 Vaccines Using A Deep Learning Approach
Amirpour, M., Shakibian, H., & Azmi, R. (2023) · International Conference on Web Research (ICWR) · doi:10.1109/icwr57742.2023.10139297 · Cited by 2
“One crucial priority for each country has been the development of effective vaccines against the virus, to control its spread and minimize its impact[10] .”
BackgroundLi, Z. Y., Qin, J., Zhang, J., Chen, Y., Yu, D., Zhang, Y., Yang, S., Li, Z., Zheng, J., Cai, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef1695 · Cited by 2
Rare cerebral vein thrombosis and COVID-19 vaccine: the role of orbit ultrasound
Lochner, P., Fousse, M., Goi, J. R., et al. (2022) · Neurological Sciences · doi:10.1007/s10072-021-05839-2 · Cited by 2
“Given the chronological relationship of disease with COVID-19 vaccination, we believe that the use of oral contraceptive pills and vaccination have contributed to the cerebral venous sinus thrombosis [4].”
BackgroundDelivery strategies of messenger RNA therapeutics for brain disorders
Youn, K., Oh, S., Gil, H.-W., Choi, Y., Keum, G., & Bang, E. (2025) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.70083 · Cited by 4
Case–control study on risk factors for in-hospital mortality in patients with severe COVID-19
Wu, K., Yin, L., Han, J., Cai, Q.-H., Guo, Y., Jin, X., Wu, J., & Cheng, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1424720 · Cited by 2
Malik, S. A., Modarage, K., & Goggolidou, P. (2022) · F1000Research · doi:10.12688/f1000research.122820.2 · Cited by 2
“The BNT162b2 and mRNA-1273 vaccines both demonstrated a ~95% and ~94.1% efficacy at preventing COVID-19 in the general population respectively, during phase III clinical trials (ClinicalTrials.gov number: NCT04470427; Clin-icalTrials.gov number: NCT04368728) (Polack et al., 2020; Baden et al., 2021).”
InfluentialKnowledge, attitude, and acceptance of COVID-19 vaccine in pregnant women
Kuptarak, A., & Phupong, V. (2024) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355241278832 · Cited by 5
Nirenberg, E., & Perencevich, E. N. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad124 · Cited by 2
Kamal, M. A., Kuznik, A., Qi, L., Więcek, W., Hussein, M. A., Hassan, H. E., Patel, K., Obadia, T., Toroghi, M. K., Conrado, D. J., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2728 · Cited by 2
COVID-19-related cardiac lesion: The questions of pathogenesis and diagnostics
Filatova, D. A., Mershina, E. A., & Sinitsyn, V. E. (2023) · Digital Diagnostics · doi:10.17816/dd284706 · Cited by 2
Ren, K., Yu, C., Yang, Q., Zhang, Q., & Li, P. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503644 · Cited by 3
Self-citationSy, M. Y., Fromm, E., Doan, L., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001112 · Cited by 2
“The mRNA vaccines from Pfizer (BNT162b2) and Moderna (mRNA1273) are notable achievements, highly effective in preventing severe COVID-19 syndromes.(2,3) Our second patient reported typical side effects including fever, fatigue, headache, chills, and muscle pain, whereas the first patient had no side effects.”
BackgroundUniversity personnel and students’ perspective on COVID-19 vaccine acceptability
Santiago, J. M., & Santos, A. R. (2022) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v11i2.21120 · Cited by 6
“The first vaccines to be marketed were the Pfizertozinameran Comirnaty® [19] and Moderna [20] vaccines, followed by the vaccines from AstraZeneca Vaxzevria® [21].”
MethodAl-Taee, S. M. Y., Al-Ani, A. G. O., & Salih, M. M. (2022) · Journal of University of Babylon for Pure and Applied Sciences · doi:10.29196/jubpas.v30i1.4071 · Cited by 3
Vaccines: past, present and future
Berdeu, I., Spătaru, D., & Paraschiv, A. (2021) · One Health & Risk Management · doi:10.38045/ohrm.2021.2.04 · Cited by 3
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study
Castro, D. V., Zengin, Z. B., Malhotra, J., Bergerot, C. D., Meza, L., Dizman, N., Govindarajan, A., Hsu, J., Chehrazi‐Raffle, A., Chawla, N. S., et al. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2136683 · Cited by 2
Ortiz-de-Lejarazu, R., Quiroga, B., & García, A. L. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.04.009 · Cited by 3
Trials and Tribulations of MicroRNA Therapeutics
(2023) · doi:10.20944/preprints202312.1888.v1 · Cited by 2
Musaddaq, B., Brown, A., Dluzewski, S., et al. (2021) · BJR|case reports · doi:10.1259/bjrcr.20210063 · Cited by 2
Zampieri, F. G., Westphal, G. A., Santos, M. A. D., Gomes, S. P. C., Gomes, J. O., Negrelli, K. L., Santos, R. H. N., Ishihara, L. M., Miranda, T. A., Laranjeira, L. N., et al. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154892 · Cited by 2
COVID-19 in Pregnancy: An Update for Clinicians
Packer, C. H., & Prabhu, M. (2024) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000885 · Cited by 2
“55 In a recent analysis of infants younger than age 6 months focused on the Omicron wave, COVID-19 vaccination in pregnancy was most effective to prevent SARS-CoV-2 infection in infants below 3 months of age (vaccine efficacy 54%); vaccine efficacy at 6 months of age was 35%.”
Vronsky, D., Hershkowitz, S., Hershko, A. Y., & Eliakim‐Raz, N. (2022) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2022_003381 · Cited by 2
“Fever, and especially high grade fever, was not prevalent[2,3].”
BackgroundWu, Y., Wang, X., Huang, Y., Chen, R., Xu, Y., Wei, W., Qin, F., Yuan, Z., Su, J., Xiu, C., et al. (2024) · Viruses · doi:10.3390/v16091481 · Cited by 2
“Although several clinical trials [3–5] and real-world studies [6] have demonstrated the effectiveness of different vaccines against COVID-19 infection, these studies have not provided sufficient information on the immunogenicity of the vaccine in immunocompromised individuals.”
BackgroundObjective and Subjective COVID-19 Vaccine Reactogenicity by Age and Vaccine ManufacturerPreprint
Presby, D. M., & Capodilupo, E. R. (2021) · medRxiv · doi:10.1101/2021.04.29.21256255 · Cited by 2
Plaxco, A. P., Kmet, J. M., Smeltzer, M. P., Jiang, Y., Taylor, M., & Nolan, V. G. (2024) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355241278852 · Cited by 2
Davidov, Y., Indenbaum, V., Mandelboim, M., Asraf, K., Gonen, T., Tsaraf, K., Cohen‐Ezra, O., Likhter, M., Nemet, I., Kliker, L., et al. (2023) · Viruses · doi:10.3390/v15010253 · Cited by 2
Otitis Media with ANCA-Associated Vasculitis Following COVID-19 mRNA Vaccination: A Case Report
Yoshino, Y., Yamanaka, Y., & Oda, A. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.945301 · Cited by 2
“Common adverse events reported with COVID-19 mRNA vaccination include fever, fatigue, myalgia, arthralgia, and headache [2,3].”
BackgroundSprečo, A., Dahlström, Ö., Jöud, A., Nordvall, D., Fagerström, C., Blomqvist, E., Gustafsson, F., Hinkula, J., Schön, T. B., & Timpka, T. (2022) · Vaccines · doi:10.3390/vaccines10081273 · Cited by 2
“7) variant circulating at that time [13].”
Đurić-Petković, D., Šuljagić, V., Begović-Kuprešanin, V., Rančić, N., & Nikolić, V. (2024) · Vaccines · doi:10.3390/vaccines12020211 · Cited by 3
“At the end of 2020, after numerous experimental studies [1–4], different types of vaccines against the coronavirus disease of 2019 (COVID-19) became available in the wider population, as one of the most significant and effective measures to prevent COVID-19.”
BackgroundGupta, A., Rajan, V., Aravindakshan, R., & Sirisha, P. (2025) · Cureus · doi:10.7759/cureus.80597 · Cited by 2
“Vaccination, particularly with mRNA-based vaccines, has been shown to attenuate systemic inflammation and limit viral replication, potentially reducing the risk of persistent symptoms [28].”
Takagi, Y., Nishimura, T., Aktar, S., Katayama, D., Takashima, K., Kawakita, T., Sekiya, T., Shingai, M., Tanaka, H., Akita, H., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102784 · Cited by 2
Nafilyan, V., Bermingham, C., Ward, I., Morgan, J., Zaccardi, F., Khunti, K., Stanborough, J., & Banerjee, A. (2022) · medRxiv · doi:10.1101/2022.03.22.22272775 · Cited by 2
Okumura, K., Hara, A., Inada, I., Sugiyama, D., Hoshino, T., Yakoh, T., Yokoyama, H., & Urushihara, H. (2022) · Vaccines · doi:10.3390/vaccines10091461 · Cited by 3
“This difference may be associated with the difference in the reporting rate of fever compared with the present study [2].”
ResultRisco-Risco, C., Martínez‐Urbistondo, D., Carrero, R. S. D. V., Ayerbe, L., Pérez-Rubio, A., Barberán-López, J., Andaluz‐Ojeda, D., & Fernández, P. V. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/017.2023 · Cited by 2
Meo, A. D., Ma, L., Yau, K., Abe, K. T., Colwill, K., Gingras, A., Kozak, R. A., Hladunewich, M., & Yip, P. S. F. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110681 · Cited by 2
The future of vaccination in Latin America: learning from the COVID-19 pandemic
Díaz, F. A. E., Arruvito, L., & Geffner, J. R. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102390 · Cited by 2
Report on adverse reactions to novel coronavirus vaccines
Matsumoto, N., Higuchi, C., Mitsuhashi, T., Hagiya, H., Takao, S., & Yorifuji, T. (2022) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.134.35 · Cited by 4
A simple non-invasive C reactive protein-based score can predict outcome in patients with COVID-19Preprint
Scotto, R., Lanzardo, A., Buonomo, A., Pinchera, B., Cattaneo, L., Sardanelli, A., Mercinelli, S., Viceconte, G., Zappulo, E., Villari, R., et al. (2022) · medRxiv · doi:10.1101/2022.09.29.22280522
“After 2 years of pandemic, the efforts in the research headed to the development of vaccines with excellent effectiveness and safety profile in the prevention of COVID-19 (2-4).”
BackgroundPrevalence and prognostic implications of myocardial injury across different waves of COVID-19
Peiró, Ó. M., Delgado-Cornejo, J. R., Sánchez-Giménez, R., Del-Moral-Ronda, V., Lal-Trehan, N., Rocamora-Horrach, M., Carrasquer, A., Peraire, J., Fort-Gallifa, I., & Bardajı́, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1297824 · Cited by 4
Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients
Schmieszek, J., Fuehner, T., Renger, I., Welte, T., Menne, J., Fuge, J., Klooster, M. P. V., Paul, A., Siegert, A., Borchina, D., et al. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14137 · Cited by 2
“Despite the widespread availability and use of vaccination [1, 2] including booster shots [3], pharmacologic treatment options are still limited, especially for those in critical condition, who are nowadays mostly unvaccinated.”
Lee, K., Park, I. H., Oh, S. C., Seo, J. H., Jeon, M. J., Yu, E. S., Kim, D. S., Choi, C. W., Lim, A.-R., Hyun, M. H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5400 · Cited by 2
Relationships between vaccination, age, and mortality in the COVID-19 intensive care patients
Demir, İ., YILMAZ, R. S., KÖSE, B., Özkarakaş, H., & Çalık, Ş. (2022) · The European Research Journal · doi:10.18621/eurj.1071588 · Cited by 2
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 3
“These vaccines showed over 90% efficacy in the prevention of symptomatic COVID-19 during large randomized trials (3, 4), and their effectiveness was corroborated by a multitude of studies in large health systems around the world (5–14).”
BackgroundGuo, Y., Cowman, K., Chang, M. H., Bao, H., Golia, A., McSweeney, T. D., Bard, L., Simpson, R., Andrews, E., Pirofski, L., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07626-6 · Cited by 3
Advancements in Nanostructured Lipid Carriers and its Patent Innovations
Mishra, A. S., Sharma, S., Bhatnagar, P., & Banik, B. K. (2024) · Current Nanomedicine · doi:10.2174/0124681873339038241211164519 · Cited by 2
Jung, M. (2024) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.23.381 · Cited by 2
Eckermann, S. D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1085319 · Cited by 2
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2
Kattih, Z., Moore, J., Stefanov, D. G., Makkar, P., & Laktičová, V. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.01.001 · Cited by 2
COVID-19 vaccine short-term adverse events in the real-life family practice in Krakow, Poland
Oleszczyk, M., Marciniak, Z., Nessler, K., et al. (2022) · European Journal of General Practice · doi:10.1080/13814788.2022.2147500 · Cited by 2
“In December 2020, supported by the evidence on the first mRNA vaccine (mRNAV) [4], the US Food and Drug Administration gave emergency authorisation to use this vaccine in the general population [5].”
BackgroundEmergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19
Vidian, V., Dikson, Litanto, V., Christy, S. N. A., & Jo, J. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00084 · Cited by 2
Huang, W., Lai, C.-Y., Liu, H., Chen, Y., Tsai, H.-C., Liu, P., & Cheng, S. (2023) · Formosan Journal of Surgery · doi:10.1097/fs9.0000000000000051 · Cited by 2
Yalçın, S., Coşgun, Y., Dedeoğlu, E., Kopp, K., Bayrakdar, F., Ünal, G., Musul, B., Sağtaş, E., Korukluoğlu, G., Raftery, P., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1332109 · Cited by 6
Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling Study
Neofotistos, G., Angeli, M., Mattheakis, M., et al. (2022) · Viruses · doi:10.3390/v14102237 · Cited by 2
“95 [16], and ε = 1/14, as fixed parameters.”
BackgroundDynamics of B-Cell Responses after SARS-CoV-2 Vaccination in Spain
José-Cascón, M. S., de la Varga‐Martínez, R., Campos‐Caro, A., & Rodriguez, C. S. (2022) · Vaccines · doi:10.3390/vaccines10101615 · Cited by 3
“These differences in the receptor expression profile in PB could be due to the type of vaccine we have used in each case: mRNA vaccine (SARS-CoV-2 mRNA BNT162b2S) and protein vaccines (plus adjuvants) in the case of the TT vaccine.”
BackgroundMethodInfluentialSila, T., Suriyaamorn, W., Toh, C., Rajborirug, S., Surasombatpattana, S., Thongsuksai, P., Kongkamol, C., Chusri, S., Sornsenee, P., Wuthisuthimethawee, P., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1350304 · Cited by 3
Camposano, J. A., Ong‐Lim, A. L., Pantig, F. M., Tarnate, P. S., Maramba-Lazarte, C. C., Cruz, L. A. D., Luna, I., Padua, J. R., Rivera, A., Ulob-Torio, M. K., et al. (2021) · Pediatric Infectious Disease Society of the Philippines Journal · doi:10.56964/pidspj2021220112 · Cited by 2
Taşçı, Y. Y., İçöz, M., İçöz, Ş. G. G., Sarıtaş, Ö., Yorgun, M. A., & TOKLU, Y. (2024) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2024.2408683 · Cited by 2
Health Consequences of University Employees Post-COVID-19 Vaccination at Palestinian Universities
Shouli, M. M., Ayed, A., Shouli, K. M., Issa, B. M., & Khraiwesh, I. (2022) · SAGE Open Nursing · doi:10.1177/23779608221144935 · Cited by 4
Kaushal, A. (2021) · ACTA SCIENTIFIC MICROBIOLOGY · doi:10.31080/asmi.2021.04.0797 · Cited by 2
The time course of in vivo cellular responses to LNPs
Loughrey, D., Paunovska, K., Echeverri, E. S., Tiegreen, K. E., & Dahlman, J. E. (2025) · Chemical Communications · doi:10.1039/d4cc06659f · Cited by 4
COVID-19 in retrospect: Public health lessons from a global crisis
Bratzler, D. W. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.008 · Cited by 7
Chen, P., Young, T., Lin, C.-Y., Kang, K., Chu, C., Tsai, H.-T., & Lin, H. (2025) · Otology & Neurotology · doi:10.1097/mao.0000000000004509 · Cited by 2
Mehmood, M. S., & Hajj, F. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004174 · Cited by 2
“Messenger RNA (mRNA) vaccines have redefined immunotherapy, with global COVID-19 vaccination exceeding 13.5 billion doses and demonstrating platform safety across diverse populations [ 1 ] .”
InfluentialWhat Clinicians Should Know about COVID-19? A review article
Kalabamu, F. S. (2021) · Microbes and Infectious Diseases /Microbes and Infectious Diseases · doi:10.21608/mid.2021.62115.1118 · Cited by 1
Immunogenicity of COVID-19 Vaccination in People Living with HIV: Progress and Challenges
Song, J., Shen, L., & Wang, F. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000073 · Cited by 3
How SARS-CoV-2 Alters the Regulation of Gene Expression in Infected Cells
Bignon, E., Grandemange, S., Dumont, E. E., & Monari, A. (2023) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.3c00582 · Cited by 2
Immune Response to SARS-CoV-2 Vaccination in Cancer Patients: A Prospective Study
Caramujo, C., Gomes, I. F., Fraga, T., et al. (2023) · Cureus · doi:10.7759/cureus.37014 · Cited by 2
“However, cancer patients were known to be grossly under-represented in the approval studies, and the large-scale studies demonstrating the efficacy of the second dose of vaccine in preventing COVID-19 either did not provide data for patients on anti-neoplastic therapy or excluded individuals on immunosuppressive thera…”
ResultSchroth, D., Garg, R., Bocova, X., Hansmann, J., Haass, M., Yan, A. T.-K., Fernando, C., Chacko, B. R., Oikonomou, A., White, J. A., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1204232 · Cited by 2
“31 Other Combinations (%) 4 (7) 1 (8) 2 (5) 1.”
InfluentialIdentifying and reducing risks of neurological complications associated with vaccination
Handunnetthi, L., Ramasamy, M., Turtle, L. C. W., & Hunt, D. P. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01000-7 · Cited by 4
“These disorders range from common mild and self-limiting adverse effects such as headache 7 or injection-site paraesthesia, to very rare but severe complications such as GBS or cerebral venous sinus thrombosis 6 (CVST).”
ElRaouf, H. M. A., Aref, A. M., Elsherif, A. K., et al. (2022) · Journal of Physics Conference Series · doi:10.1088/1742-6596/2304/1/012002 · Cited by 2
“d death rate of I due to disease Per day [1] r Infectious class recovery rate Per day [1] α Vaccination rate of population Per day [19] σ The vaccine inefficacy Dimensionless [13] Rate of vaccinated people who turned to recovered class Per day [19]”
BackgroundBosinger, S. E., Edwards, C. T., Karunakaran, K. A., Garcia, E., Beutler, N., Gagné, M., Golden, N., Aoued, H., Pellegrini, K., Burnett, M. R., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012456 · Cited by 3
The rapidly emerging field of RNA therapies for cardiovascular disease
Cooke, J. P. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000121 · Cited by 2
Assessment of the feasibility of pool testing for SARS-CoV-2 infection screening
Paganini, I., Sani, C., Chilleri, C., Baccini, M., Antonelli, A., Bisanzi, S., Burroni, E., Cellai, F., Coppi, M., Mealli, F., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2044512 · Cited by 2
The Effects of Expectations and Worries on the Experience of COVID-19 SymptomsPreprint
Akintola, T., Chung, J. Y., & Atlas, L. Y. (2023) · medRxiv · doi:10.1101/2023.01.26.23284911 · Cited by 1
“26 In fact, a few studies investigating COVID-19 vaccine hesitancy and the experience of adverse effects report 27 that fear and negative expectations may have induced adverse effects in vaccine trials (Polack 2020), consistent 28 with nocebo effects.”
Background(2021) · doi:10.1101/2021.03.19.21253960 · Cited by 101
Use of Bayesian approaches in oncology clinical trials: A cross-sectional analysis
Lopez-Rey, B. G., Carot-Sans, G., Ouchi, D., Torres, F., & Pontes, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1548997 · Cited by 4
Begum, A., Uddin, M. A., Ahsan, S. M., & Islam, M. A. (2025) · Health Science Reports · doi:10.1002/hsr2.71066 · Cited by 2
Schmetz, A., Knaul, J. K., Müller, S., Wilke, T., Yang, J., Spinner, C. D., & Lehmann, C. (2026) · Eurosurveillance · doi:10.2807/1560-7917.es.2026.31.15.2500672 · Cited by 2
Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. CitiesPreprint
Gaddis, S. M., Carey, C., & DiRago, N. V. (2021) · medRxiv · doi:10.1101/2021.12.01.21267158 · Cited by 2
Wratil, P. R., Kotter, K., Bischof, M. L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2044418/v1 · Cited by 2
Kugai, S., Aretz, B., Krumpholtz, Y., Schmidt, M., Süssle, D., Steyer, L., Henkel, A., Bender, K., Girrbach, F. F., Stehr, S. N., et al. (2024) · Healthcare · doi:10.3390/healthcare12212192 · Cited by 3
Grochowska, M., Ratajczak, A., Zdunek, G., Adamiec, A., Waszkiewicz, P., & Feleszko, W. (2021) · Vaccines · doi:10.3390/vaccines9050475 · Cited by 75
“Simultaneously, several studies were published, confirming the relatively high safety and efficacy of COVID-19 vaccinations [37-39].”
ResultPark, S., & You, J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e131 · Cited by 2
Vaccination-Associated PathogenesisPreprint
Chang, C., Yu, C., Yang, C.-C., & Hsu, S. (2024) · Preprints.org · doi:10.20944/preprints202401.1689.v1 · Cited by 1
Iwamoto, M., Ukimura, A., Ogawa, T., Kawanishi, F., Osaka, N., Kubota, M., Mori, T., Sawamura, R., Nishihara, M., Suzuki, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268529 · Cited by 3
How a mRNA COVID-19 Vaccine works inside a Cell: A Virtual Reality Serious Game
Berry, C., Wong, K. W., Wang, G., et al. (2022) · IEEE International Conference on Serious Games and Applications for Health (SeGAH) · doi:10.1109/segah54908.2022.9978562 · Cited by 2
“However, the highly conceptual nature of immune responses induced from the first delivery of the mRNA vaccines, Pfizer/Comirnaty (BNT162b2) vaccine [4] and/or the Moderna (mRNA-1273) [5], to the development of long-lasting immunity is not understood by many people lacking specific knowledge of this…”
BackgroundMullahy, J. (2021) · Health Economics · doi:10.1002/hec.4233 · Cited by 2
Augustyniak, A., Szymański, T., Porzucek, F., Mieloch, A. A., Semba, J. A., Hubert, K. A., Grajek, D., Krela, R., Rogalska, Z., Zalc-Budziszewska, E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.008 · Cited by 2
“2038539 [19] Polack FP, Thomas SJ, Kitchin N, et al.”
Chan, T. K. (2022) · Journal of Global Health · doi:10.7189/jogh.12.03004 · Cited by 2
Ben‐Tov, A., Lebwohl, B., Banon, T., Chodick, G., Kariv, R., Assa, A., Gazit, S., & Patalon, T. (2023) · Viruses · doi:10.3390/v15091968 · Cited by 2
Recent advances in LNP-mRNA vaccines
Redenti, B. J., Zhong, Y., Yu, C., & Dong, Y. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115675 · Cited by 5
Understanding the impact process of vaccine adoption for COVID-19
Zhu, W., Zou, H., Song, Y., Ren, L., & Xu, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2099166 · Cited by 4
Wang, N., Luo, R., Ji, Z.-H., Chen, Y.-H., Su, L.-J., Xu, M.-X., Yang, C., Zhang, J., Gao, Y., Xu, S., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114383 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.